USA flag logo/image

An Official Website of the United States Government

IFN-GAMMA BIOASSAYS

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
7867 		Program Year/Program:
1988 / SBIR
Agency Tracking Number:
7867 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
Medarex, Inc.
707 State Road Princeton, NJ 08540
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1988
Title: IFN-GAMMA BIOASSAYS
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

IFN- IS CURRENTLY BEING TESTED FOR THE TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING AUTOIMMUNE AND INFECTIOUS DISEASES, SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES. AS WITH OTHER BIOLOGICAL RESPONSE MODIFIERS, IT IS DIFFICULT TO PREDICT THE OPTIMAL DOSE FOR THE DESIRED IN VIVO EFFECT, AND TWO INDIVIDUALS MAY RESPOND VERY DIFFERENTLY TO THE SAME DOSE. IT IS NOW POTENTIALLY POSSIBLE TO MONITOR THE IN VIVO BIOACTIVITY OF IFN- SINCE THIS LYMPHOKINE, AND NO OTHERS TO DATE, DRAMATICALLY INCREASES THE NUMBER OF TYPE I FC RECEPTORS FOR IGG (FC RI) ON HUMAN MONOCYTES AND POLYMORPHONUCLEAR NEUTROPHILS (PMNS). MEDAREX HAS EXCLUSIVE RIGHTS TO MONOCLONAL ANTIBODIES (MABS) WHICH ARE UNIQUELY SUITED TO THE MEASUREMENT OF FC RI. RESEARCH OUTLINED IN THIS PROPOSAL IS DESIGNED TO DEVELOP AND TEST AN ELISA ASSAY FOR QUANTITATIVEANALYSIS OF BIOACTIVE IFN- , AND TO DEVELOP AND TEST MAB-BASED REAGENTS TO EVALUATE THE MAGNITUDE OF A GIVEN PATIENT'S RESPONSE TO IFN- IN VIVO. WE ANTICIPATE THAT THESE ASSAYS WILL SERVE AS PROTOTYPES FOR THE IN VIVO AND IN VITRO ANALYSIS OF RESPONSE TO OTHER IMMUNE CYTOKINES.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Medarex Inc
1401 Broad St Clifton, NJ 07015

EIN/Tax ID:
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No